Showing results (71-80 of 97) with videos related to
Sort By:
Pageof 10
Cancers|July 15, 2026
A Real-World Study on the Effectiveness and Safety of Elacestrant in Patients with <i>ESR1</i>-Mutated Metastatic Breast Cancer Progressing After CDK4/6 Inhibitors and Endocrine TherapyMartina Greco, Vittorio Gebbia, Rossana Berardi, et al.Anticancer Research|December 30, 2022
A Prospective Observational Study on the Structuring Process and Implementation of a Large Regional, Inter-hospital, Virtual Multidisciplinary Tumor Board on Prostate CancerMaria Rosaria Valerio, Vincenzo Serretta, Demetrio Arico, et al.Breast Cancer Research and Treatment|December 7, 2010
Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancerDino Amadori, Rosella Silvestrini, Mario De Lena, et al.Lung Cancer (Amsterdam, Netherlands)|April 22, 2009
Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trialsCesare Gridelli, Alessandro Morabito, Vittorio Gebbia, et al.Oncology Reports|April 2, 2011
Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patientsDaniele Santini, Bruno Vincenzi, Vincenzo Adamo, et al.BMC Cancer|January 10, 2006
Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective studySandro Pignata, Sabino De Placido, Rosalbino Biamonte, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2004
Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized studySabino De Placido, Giovanni Scambia, Giovanni Di Vagno, et al.Oncology Reports|July 29, 2003
Nm23-H1 expression does not predict clinical survival in colorectal cancer patientsLuisa Dusonchet, Simona Corsale, Manuela Migliavacca, et al.NPJ Breast Cancer|September 8, 2023
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancerAlessandra Fabi, Luisa Carbognin, Andrea Botticelli, et al.Pulmonary Therapy|June 5, 2021
Virtual Multidisciplinary Tumor Boards: A Narrative Review Focused on Lung CancerVittorio Gebbia, Aurelia Guarini, Dario Piazza, et al.Pageof 10